Redag off to flying start with major R&D deal

Redag off to flying start with major R&D deal

Redag Crop Protection – the Cheshire-based discovery business – has signed a major R&D agreement with one of the top ten players in the agrochemical market to collaborate on the development of new pesticides.

Redag Crop Protection will give exclusive access to two of its areas of chemistry and will apply its Redox SwitchTM methodology to create compounds with the potential to become new products. In return, Redag will receive multiple six-figure payments.

Ultimately Redag will enter into a development agreement with its partner for some of these compounds in exchange for multimillion milestone payments and royalties on sales. The deal comes less than nine months after Redag demerged from its parent company Redx Pharma and moved into new premises in Alderley Park with backing from The North West Fund for Venture Capital, existing Redx shareholders and new private investors in a transaction which was coordinated by Acceleris Capital.

Bill Thompson, CEO of Redag Crop Protection, commented: “Following the fundraising in October 2014 we have established our chemistry team in Alderley Park, Cheshire and continued to develop our science. Having successfully demonstrated the technical proof of our approach to key companies in the industry, this first collaboration underlines that commercial value.

“Both parties to the agreement see this as a first step in a long-term relationship. It is a significant milestone in our progress and reinforces Redag’s position as the engine of discovery in the crop protection market.”

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.